Currently, Harvard Bioscience Inc [HBIO] is trading at $0.47, down -30.32%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HBIO shares have gain 41.43% over the last week, with a monthly amount glided 31.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Harvard Bioscience Inc [NASDAQ: HBIO] stock has seen the most recent analyst activity on April 09, 2025, when KeyBanc Capital Markets downgraded its rating to a Sector Weight. Previously, The Benchmark Company upgraded its rating to Buy on March 10, 2023, and elevated its price target to $4. On January 07, 2021, upgrade upgraded it’s rating to Buy. Northland Capital started tracking the stock assigning a Outperform rating and suggested a price target of $6 on December 09, 2020. KeyBanc Capital Markets initiated its recommendation with a Overweight and recommended $6 as its price target on November 10, 2020. Janney downgraded its rating to Neutral for this stock on July 08, 2019, but kept the price target unchanged to $2. In a note dated January 24, 2018, Janney reiterated an Buy rating on this stock and boosted its target price from $5 to $8.
This stock has fluctuated between a low of $0.28 and a high of $3.60 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Harvard Bioscience Inc [NASDAQ: HBIO] shares were valued at $0.47 at the most recent close of the market. An investor can expect a potential return of 1389.36% based on the average HBIO price forecast.
Analyzing the HBIO fundamentals
Trailing Twelve Months sales for Harvard Bioscience Inc [NASDAQ:HBIO] were 91.40M which represents -11.17% decline. Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at -0.48%, Pretax Profit Margin comes in at -0.63%, and Net Profit Margin reading is -0.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.73, Equity is -1.1 and Total Capital is -1.81. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.49.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4045 points at the first support level, and at 0.3421 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5554, and for the 2nd resistance point, it is at 0.6439.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Harvard Bioscience Inc [NASDAQ:HBIO] is 0.81. Also, the Quick Ratio is 0.40, while the Cash Ratio stands at 0.1. Considering the valuation of this stock, the price to sales ratio is 0.23, the price to book ratio is 1.39.
Transactions by insiders
Recent insider trading involved Green James W, Chief Executive Officer, that happened on Jun 13 ’24 when 10000.0 shares were purchased. Chief Executive Officer, Green James W completed a deal on Jun 06 ’24 to buy 20000.0 shares.
